LAG3 antibody (N-Term) (Atto 647N)
Quick Overview for LAG3 antibody (N-Term) (Atto 647N) (ABIN1169111)
Target
See all LAG3 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- N-Term
-
Specificity
- Recognizes human LAG-3.
-
Cross-Reactivity
- Human
-
Purity
- >95 % (SDS-PAGE)
-
Immunogen
- Synthetic peptide corresponding to 30 aa in the N-terminus of human LAG-3.
-
Isotype
- IgG1
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
New ATTO-fluorescent antibodies show increased photostability, outstanding brightness and intense signals. ATTO dyes are thermally stable, resistant to environmental changes and show no significant isomerization. ATTO 647N shows red fluorescence (lambdaabs (max): 645nm, lambdaem (max): 669nm, epsilonmax: 120'000).
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- Lot specific
-
Buffer
- In PBS containing 0.02 % sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C
-
Storage Comment
-
Short Term Storage: +4°C
Long Term Storage: +4°C
Keep conjugated formats at +4°C. Stable for at least 1 year after receipt when stored at +4°C. -
Expiry Date
- 12 months
-
-
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
-
Alternative Name
- LAG-3
-
Background
- Lymphocyte activation gene 3 (LAG-3, CD223) plays an important role in negatively regulating T cell proliferation, function and homeostasis. It is required for maximal natural and induced regulatory T cell (Treg) function. LAG-3 is closely related to the T cell co-receptor CD4 and binds to MHC class II molecules but with a significantly higher affinity than CD4.
-
UniProt
- P18627
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Target
-